Wu, J.C., et al., Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition
Tumor risk via p53 pathway interference Mitigate risk by: Careful patient selection: exclude patients with pre-existing active malignancy or high tumour risk (e.g., known p53 mutations, familial cancer syndromes)
Content may require purchase if you do not have access.) Article purchase Temporarily unavailable References Ballatori, N, Krance, SM, Notenboom, S, et al
Informational only not medical, financial, or insurance advice
Zhang Q, Delessa CT, Augustin R, et al
Baig AM, Khaleeq A, Ali U, Syeda H